Briviact Injection, Suspension
Product Images NDC 50474-970

9 FDA label images from Ucb, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Briviact (NDC 50474-970). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ucb, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Briviact 01)

Chemical Structure (Briviact 01)
Chemical structure diagram of brivaracetam, the active ingredient in Briviact. The structure shows the molecular arrangement including the pyrrolidinone ring and functional groups characteristic of brivaracetam.*
FDA Label Image

Figure 1 (Briviact 02)

Figure 1 (Briviact 02)
A bar chart showing the proportion of patients (%) at different ranges of reduction in seizure frequency from baseline (%) for placebo and Briviact (brivaracetam) at doses of 50 mg/day, 100 mg/day, and 200 mg/day. The x-axis categorizes seizure frequency reduction into groups: Worse, 0 to <25, 25 to <50, 50 to <75, and 75 to 100. The y-axis represents the proportion of patients in each category.*
FDA Label Image

Principal Display Panel (10 mg Tablet Bottle Carton)

Principal Display Panel (10 mg Tablet Bottle Carton)
Packaging label for Briviact (brivaracetam) tablets 10 mg by UCB, Inc. The label is for a 60-tablet carton, with dosage form film-coated oral tablets. It includes storage instructions, a barcode, NDC 50474-370-66, and a pharmacist advisory to dispense medication guide to patients. The product is made in Belgium.*
FDA Label Image

Principal Display Panel (25 mg Tablet Bottle Carton)

Principal Display Panel (25 mg Tablet Bottle Carton)
Briviact 25 mg tablets packaging label. The tablet film-coated oral medication is branded as BRIVIACT with the generic name brivaracetam. The label includes dosage strength, barcode, storage instructions, and pharmacist dispensing guidance. Manufactured by UCB, Inc. The box contains 60 tablets and displays the NDC 50474-470-66.*
FDA Label Image

Principal Display Panel (50 mg Tablet Bottle Carton)

Principal Display Panel (50 mg Tablet Bottle Carton)
Box label for Briviact (brivaracetam) tablets, 50 mg strength. The label displays the product name, strength, and oral tablet dosage form. It states the manufacturer as UCB, Inc., Smyrna, GA. The label includes storage instructions, a barcode, NDC 50474-570-66, and indicates a count of 60 tablets. It advises dispensing a medication guide to the patient.*
FDA Label Image

Principal Display Panel (75 mg Tablet Bottle Carton)

Principal Display Panel (75 mg Tablet Bottle Carton)
Packaging label for Briviact (brivaracetam) 75 mg film-coated tablets. The label indicates 60 tablets per package, manufactured by UCB, Inc., Smyrna, GA, made in Belgium. It includes dosage instructions, storage conditions, and a barcode. The NDC is 50474-670-66.*
FDA Label Image

Principal Display Panel (100 mg Tablet Bottle Carton)

Principal Display Panel (100 mg Tablet Bottle Carton)
Packaging label for Briviact (brivaracetam) tablets 100 mg, film-coated oral tablets by UCB, Inc. The label states the product name, strength, dosage form, and manufacturer. It includes storage instructions, a barcode, NDC 50474-770-66, quantity of 60 tablets, and a pharmacist warning to dispense the medication guide with the product.*
FDA Label Image

Principal Display Panel (300 mL Bottle Carton)

Principal Display Panel (300 mL Bottle Carton)
Packaging label for Briviact (brivaracetam) oral solution 10 mg/mL by UCB, Inc. The label specifies a 300 mL bottle, includes storage instructions, pharmacist dispensing guidance, and a barcode. The product is manufactured for UCB, Inc., Smyrna, GA, made in Belgium, and emphasizes keeping out of reach of children.*
FDA Label Image

Principal Display Panel (10 Vial Carton)

Principal Display Panel (10 Vial Carton)
Packaging label for Briviact (brivaracetam) injection, 50 mg/5 mL (10 mg/mL), for intravenous use only. The label indicates the product is manufactured for UCB, Inc. and is supplied as 10 vials per package. The label includes storage instructions and a barcode, along with the proprietary and generic names.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.